Company intelligence / Profile preview

Nuvaira

Minneapolis/Plymouth, Minnesota, United Statesnuvaira.com ↗

Ownership: Private
Employees: ~30
Development stage: Phase 3

Overview

The dNerva® Targeted Lung Denervation System has demonstrated a significant reduction in severe COPD exacerbations and stable quality of life and lung function over two to three years post-procedure. The AIRFLOW clinical trial program includes pivotal studies such as AIRFLOW‑3. The device has CE Mark approval in Europe but remains investigational in the US.

Therapeutic areas: Pulmonology
Modalities: DeviceNon-pharmacological therapyCatheter-based system
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

dNerva Lung Denervation System

Phase 3

Indications: COPD, Asthma

Partnerships

Supported by educational grants from Janssen Scientific Affairs and Seagen for related educational activities; no major disclosed pharma/biotech development partnerships.

Beyond the preview

Go deeper on Nuvaira.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuvaira.

Explore the full profile